TrialBritish journal of haematology2023

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.

Johnny N Mahlangu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.